malonic acid has been researched along with Akinetic-Rigid Variant of Huntington Disease in 18 studies
malonic acid : An alpha,omega-dicarboxylic acid in which the two carboxy groups are separated by a single methylene group.
dicarboxylic acid : Any carboxylic acid containing two carboxy groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malonic acid is a reversible inhibitor of mitochondrial enzyme complex-II, induces energy crisis and free radical generation." | 1.72 | Protective effect of 3-n-butylphthalide against intrastriatal injection of malonic acid-induced neurotoxicity and biochemical alteration in rats. ( Yuan, C; Zhao, Y; Zheng, L, 2022) |
| "Malonic acid (MA) is a reversible inhibitor of succinate dehydrogenase (SDH) which induces mitochondrial dysfunction followed by secondary excitotoxicity and apoptosis due to generation of reactive oxygen species." | 1.39 | Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. ( Kalonia, H; Kumar, A; Mishra, J; Sharma, N, 2013) |
| "Cystamine treatment of various genetic models of HD demonstrated protection against neurodegeneration and/or improvement in behavior." | 1.37 | Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. ( Leavitt, BR; Sivananthan, SN, 2011) |
| "Transgenic Huntington's disease (HD) mice, expressing exon 1 of the HD gene with an expanded CAG repeat, are totally resistant to striatal lesion induced by excessive NMDA receptor activation." | 1.31 | Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. ( Bates, GP; Brundin, P; Castilho, RF; Hansson, O; Korhonen, L; Lindholm, D, 2001) |
| "The gene defect in Huntington's disease (HD) may result in an impairment of energy metabolism." | 1.30 | Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. ( Beal, MF; Ferrante, RJ; Jenkins, BG; Kaddurah-Daouk, R; Matthews, RT; Rosen, BR; Yang, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, X | 1 |
| Zhang, H | 1 |
| Qu, T | 1 |
| Wang, Y | 1 |
| Zhong, Y | 1 |
| Yan, Y | 1 |
| Ji, X | 1 |
| Chi, T | 1 |
| Liu, P | 1 |
| Zou, L | 1 |
| Yuan, C | 1 |
| Zheng, L | 1 |
| Zhao, Y | 1 |
| Kumar, A | 2 |
| Sharma, N | 1 |
| Mishra, J | 1 |
| Kalonia, H | 2 |
| Sagredo, O | 2 |
| González, S | 1 |
| Aroyo, I | 1 |
| Pazos, MR | 1 |
| Benito, C | 1 |
| Lastres-Becker, I | 2 |
| Romero, JP | 1 |
| Tolón, RM | 1 |
| Mechoulam, R | 1 |
| Brouillet, E | 2 |
| Romero, J | 1 |
| Fernández-Ruiz, J | 4 |
| Kumar, P | 1 |
| Sivananthan, SN | 1 |
| Leavitt, BR | 1 |
| Valdeolivas, S | 1 |
| Satta, V | 1 |
| Pertwee, RG | 1 |
| Petersén, A | 1 |
| Puschban, Z | 1 |
| Lotharius, J | 1 |
| NicNiocaill, B | 1 |
| Wiekop, P | 1 |
| O'Connor, WT | 1 |
| Brundin, P | 2 |
| Bizat, N | 1 |
| Boyer, F | 1 |
| Hantraye, P | 1 |
| Alfinito, PD | 1 |
| Wang, SP | 1 |
| Manzino, L | 1 |
| Rijhsinghani, S | 1 |
| Zeevalk, GD | 1 |
| Sonsalla, PK | 1 |
| Murphy, RC | 1 |
| Messer, A | 1 |
| Klivenyi, P | 3 |
| Starkov, AA | 1 |
| Calingasan, NY | 1 |
| Gardian, G | 1 |
| Browne, SE | 1 |
| Yang, L | 2 |
| Bubber, P | 1 |
| Gibson, GE | 1 |
| Patel, MS | 1 |
| Beal, MF | 4 |
| de Lago, E | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Li, J | 1 |
| Calkins, MJ | 1 |
| Johnson, DA | 1 |
| Johnson, JA | 1 |
| Matthews, RT | 1 |
| Jenkins, BG | 1 |
| Ferrante, RJ | 3 |
| Rosen, BR | 1 |
| Kaddurah-Daouk, R | 1 |
| Andreassen, OA | 2 |
| Dedeoglu, A | 2 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Hughes, DB | 1 |
| Ona, VO | 1 |
| Friedlander, RM | 1 |
| Hansson, O | 1 |
| Castilho, RF | 1 |
| Korhonen, L | 1 |
| Lindholm, D | 1 |
| Bates, GP | 1 |
1 review available for malonic acid and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Role of Nrf2-dependent ARE-driven antioxidant pathway in neuroprotection.
Topics: Animals; Antioxidants; Cell Death; Corpus Striatum; Disease Models, Animal; Electron Transport Compl | 2007 |
17 other studies available for malonic acid and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Tolfenamic acid inhibits ROS-generating oxidase Nox1-regulated p53 activity in intrastriatal injection of malonic acid rats.
Topics: Animals; Apoptosis; Huntington Disease; Malonates; Mice; Oxidoreductases; Rats; Reactive Oxygen Spec | 2022 |
Protective effect of 3-n-butylphthalide against intrastriatal injection of malonic acid-induced neurotoxicity and biochemical alteration in rats.
Topics: Animals; beta Catenin; Huntington Disease; Nerve Growth Factors; Neuroprotective Agents; Neurotoxici | 2022 |
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.
Topics: Animals; Arachidonic Acids; Camphanes; Cannabinoids; Cell Death; Central Nervous System Agents; Corp | 2009 |
Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats.
Topics: Animals; Body Weight; Disease Models, Animal; Drug Delivery Systems; Huntington Disease; Lipid Perox | 2010 |
Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
Topics: Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Eicosapentaenoic Acid; Huntington Disea | 2011 |
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Topics: Animals; Cannabidiol; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Combinations; Drug Ther | 2012 |
Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice.
Topics: Animals; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Fluorescent Dyes; Hu | 2002 |
Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
Topics: Animals; Cannabinoid Receptor Modulators; Cannabinoids; Corpus Striatum; Disease Models, Animal; Dro | 2003 |
Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Str | 2003 |
A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease.
Topics: Animals; Animals, Newborn; Biolistics; Cell Aggregation; Cell Count; Cell Death; Corpus Striatum; Cu | 2004 |
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cell Count; Cerebral Cortex; | 2004 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Antineoplastic Agents; Creatine; Creatinin | 1998 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant.
Topics: Animals; Brain; Caspase 1; Crosses, Genetic; Disease Models, Animal; Female; Huntington Disease; Mal | 2000 |
Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Topics: Aging; Amino Acid Chloromethyl Ketones; Animals; bcl-X Protein; Blood Glucose; Cell Death; Corpus St | 2001 |